Head to Head Analysis: 21st North (ULGX) and Viveve Medical (VIVE)

21st North (OTCMKTS:ULGX) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares 21st North and Viveve Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
21st North N/A N/A N/A
Viveve Medical -243.98% -838.28% -104.99%

Analyst Ratings

This is a breakdown of current ratings for 21st North and Viveve Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
21st North 0 0 0 0 N/A
Viveve Medical 0 1 5 0 2.83

Viveve Medical has a consensus price target of $8.75, suggesting a potential upside of 351.03%. Given Viveve Medical’s higher possible upside, analysts plainly believe Viveve Medical is more favorable than 21st North.

Institutional and Insider Ownership

0.2% of 21st North shares are held by institutional investors. Comparatively, 52.1% of Viveve Medical shares are held by institutional investors. 8.5% of 21st North shares are held by insiders. Comparatively, 35.1% of Viveve Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

21st North has a beta of 6.17, meaning that its share price is 517% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500.

Earnings & Valuation

This table compares 21st North and Viveve Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
21st North N/A N/A N/A N/A N/A
Viveve Medical $15.29 million 4.00 -$36.95 million ($2.11) -0.92

21st North has higher earnings, but lower revenue than Viveve Medical.

Summary

Viveve Medical beats 21st North on 5 of the 9 factors compared between the two stocks.

About 21st North

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

About Viveve Medical

Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Receive News & Ratings for 21st North Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 21st North and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply